As we learned earlier in the course, PTSD has very specific diagnostic criteria as laid out in the DSM, however we know that the symptomology of post-traumatic stress is much more diverse than this.
Complex post-traumatic stress disorder, on the other hand, is not listed in the DSM, it is listed in the International Classification of Diseases (ICD) which we will reference in this module to help frame the diagnostic criteria.
Due to the nature of this topic, some may find this module activating. We encourage you to take breaks as much as you need as you work through this content. Please reach out to training@numinus.com if you need support.
In addition to the diagnostic criteria for PTSD, the ICD specifies three additional criteria for C-PTSD:
Complex Post-Traumatic Stress Disorder (C-PTSD) symptoms may appear at any point in a person's life, usually following exposure to continuous and recurring traumatic events or victimization that lasts for months or even years. C-PTSD symptoms are typically more severe and long-lasting compared to those of Post-Traumatic Stress Disorder (PTSD). Experiencing repeated traumatic events, particularly during early development, increases the likelihood of developing C-PTSD rather than PTSD (World Health Organization, 2019).
Current treatment approaches to C-PTSD are similar to the treatment of PTSD, and the triphasic (3-phase) approach to treatment is advised. As discussed in Module 3, the first phase is stabilization and skills strengthening, which aims to ensure safety, reduce symptoms, and build basic psychosocial skills. The second phase is trauma processing and integration, while the third phase involves transitioning treatment gains to everyday life, such as social relationships and work or education (Oehen & Gasser, 2022). As we have previously covered in this course, during psychedelic-assisted therapy, all three phases may be encountered across the arc of preparation through to integration of Medicine Sessions. This is in part owing to the likelihood of psychedelic medicines to surface repressed emotions and memories. It may be more challenging for the health professional to pace phase two during a Medicine Session. For this reason, we recommend a low threshold for recommending additional preparation time for people with C-PTSD, who may benefit from additional stabilization and skills strengthening prior to dosing sessions.
What other improvements can a triphasic approach bring in addition to relieving symptoms of PTSD and C-PTSD?
The triphasic approach can improve outcomes not only in relation to symptoms of PTSD, but also in addressing other significant aspects of the condition such as difficulties in regulating emotions, impaired ability to form and maintain relationships, changes in attention and consciousness (such as dissociation), negative beliefs, and bodily distress. For this reason, we recommend structuring your approach in all persons presenting with post-traumatic symptoms with the triphasic framework in mind. Furthermore, in all cases, treatment should be tailored to the specific needs of each client, keeping the most significant symptoms they are experiencing in mind (Cloitre et al., 2011), while incorporating process-based approaches that help individuals learn to relate to their experiences with enhanced psychological flexibility and greater choice.
Unfortunately, few studies have focused specifically on treating C-PTSD with psychedelic medicines. More studies are needed in this area, however parallels can be drawn between treating PTSD and C-PTSD with psychedelic medicines.
Cloitre, M., Courtois, C. A., Charuvastra, A., Carapezza, R., Stolbach, B. C., & Green, B. L. (2011). Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practices. Journal of traumatic stress, 24(6), 615–627.
Oehen, P., & Gasser, P. (2022). Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders. Frontiers in Psychiatry, 13, Article 863552.
World Health Organization. (2019). ICD-11: International Classification of Diseases 11th Revision.